Intuitive Surgical

Intuitive Surgical Stock Rockets 17% After Blowout Q3 Earnings – Is $600 Next?

Intuitive Surgical’s da Vinci surgical robot in an operating room setting. Intuitive’s stock jumped on Oct. 21 after the company reported blowout Q3 results and raised full-year guidance reuters.com ts2.tech. The quarter’s 23% revenue growth was driven by a surge in robot-assisted procedures, as hospitals resume elective surgeries and expand minimally-invasive care reuters.com reuters.com. Reuters notes Intuitive has seen “steady growth as hospitals work through a backlog of deferred procedures” reuters.com, reflecting post-pandemic catch-up demand. Intuitive’s CEO Dave Rosa celebrated the results. He noted “continued growth in customer use and adoption of our Ion and da Vinci platforms, including da

22 October 2025

Intuitive Surgical (ISRG) Stock Explodes 17% on Q3 Blowout – Is $600 Next?

Q3 Earnings Blowout and Stock Reaction Intuitive Surgical crushed expectations for the quarter ended Sept 30, 2025. 3Q revenue was $2.51 billion, up 23% from a year ago, versus analyst forecasts of ~$2.40 billion reuters.com. Adjusted EPS came in at $2.40 (GAAP $1.95), easily above the ~$1.99 consensus reuters.com globenewswire.com. The company reported $867 million in non-GAAP net income (versus $669 M a year prior) globenewswire.com. Notably, Intuitive repurchased $1.92 billion of stock in Q3, burning 4 million shares, which also supported EPS globenewswire.com. “We’re pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and

22 October 2025

Earnings Reports · Financial News · Healthcare Stocks · Investing · NASDAQ:ISRG · Stock Market

Intuitive Surgical Stock Primed for Rally on FDA Approvals and Congressional Buying

Stock Performance & Analyst Consensus Intuitive’s stock has been volatile in 2025. It gained ground last week on optimism (e.g. up ~2.7% on Oct. 17) and now sits around $446 investing.com marketbeat.com. Over the past year, the price swung between about $425 and $616 investing.com. At ~$446, ISRG trades at a high single-digit P/E (~60x) compared to the medtech sector, but analysts argue much of Intuitive’s growth is already priced in. Institutional sentiment is upbeat: 22 of 32 surveyed analysts rate ISRG a Buy, with an average 12-month target of roughly $576 investing.com (implying ~29% upside). For example, RBC Capital

19 October 2025

FDA Approvals · Healthcare Stocks · Investment Strategies · Medical Technology · NASDAQ:ISRG · Stock Market